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B-cells play a crucial role in the pathogenesis of systemic lupus erythematosus 
(SLE) being a source of characteristic antinuclear autoantibodies. There is 
increasing evidence that alterations in B-cell regulation are responsible for B-
cell hyperactivity as seen in SLE. T-cells, soluble factors and even B-cells 
themselves regulate effector B-cell functions. The latter, so-called regulatory B-
cells possess regulatory function via production of the cytokine IL-10 that can 
damp humoral immune responses. This review will focus on B-cell regulation in 
the pathogenesis of SLE as a target for intervention. In particular, the regulatory 
impact of T-cells via costimulation, soluble factors such as BLyS, and the 
characteristics of IL-10 producing regulatory B-cells will be discussed. 
Therapies targeting B-cells as well as B-cell regulation seem promising but the 
precise mechanisms involved in these interventions are not completely 
understood. More insight in B-cell regulation in SLE, and particularly in 
















Systemic lupus erythematosus (SLE) is a systemic autoimmune disease 
characterised by autoantibody production associated with a wide range of 
clinical manifestations. The inflammatory response triggered by in situ formation 
and/or passive deposition of immune complexes is thought to be responsible for 
various clinical manifestations such as vasculitis, nephritis and skin 
involvement.  
However, the precise etiopathogenesis of the disease remains unclear. 
It is widely accepted that B and T-cells play a pivotal role in the pathogenesis of 
SLE. Alterations of cell numbers, activation status and function in these 
lymphocyte subsets have been demonstrated. At first glance, B-cells, being a 
source of autoantibodies, are the protagonist in the immunological cascade 
ending in organ injury. There is growing evidence that, besides autoantibody 
secretion, other functions of B-cells such as antigen presenting capacity and 
cytokine production contribute to the development of SLE as well.1  
Regulation of B-cell activity is an essential part of immune homeostasis. 
T-cells play a major role in B-cell regulation. First, interaction between B and T-
cells is necessary to induce T-cell dependent autoantibody production. The best 
characterised molecular interactions between T and B-cells occur via CD28–
CD80/CD86 and CD154/CD40, respectively. Furthermore, several T-cell 
derived soluble factors play a role in B-cell homeostasis. Beside these T-cell 
dependent stimuli and interactions in B-cell activation current studies reveal the 
existence of a subset of B-cells with regulatory capacities. This regulatory 
subset is characterised by the secretion of IL-10 and TGF-β, and has been 
shown to be involved in the pathogenesis of autoimmune diseases such as 
experimental autoimmune encephalomyelitis (EAE).2;3 The existence and 
hypothetical impact of these regulatory B-cells in systemic lupus erythematosus 
remains unclear until now. However, the role of this B-cell population in different 
murine models reflects a potential target in the pathogenesis of SLE. The 
present review will shortly discuss the role of B-cells in the pathogenesis of 





This set the stage for exploring new therapeutic modalities directed at B-cell 
regulation in this disease.  
 
B-cells as effector cells in SLE 
The hallmark of immune dysregulation in SLE is B-cell hyperactivity.4 B-cells 
produce a wide range of autoantibodies against soluble and cellular 
constituents. The most characterstic autoantibodies in SLE are targeting 
constituents of the nucleus, the antinuclear antibodies (ANA). Anti-double 
stranded DNA (ds-DNA) or anti-Sm antibodies are present in more than 90 % of 
patients with SLE.5;6 
Animal models and clinical observations provide convincing evidence 
that autoantibodies play a key role in the pathogenesis of SLE. Especially anti-
dsDNA antibodies are thought to play a major role in the pathogenesis of lupus 
nephritis. Vlahakos et al. demonstrated that transfer of monoclonal anti-DNA 
antibodies (Ab) derived from MRL-lpr/lpr and (NZBxSWR)F1 mice to normal 
mice resulted in intranuclear deposits of anti-DNA Ab within glomeruli, 
associated with hypercellularity and proteinuria.7 There is also increasing 
evidence that anti-DNA antibodies have the potential to cross-react with normal 
glomerular constituents such as surface antigens on endothelial cells, 
phospholipids, laminin, type IV collagen and α-actinin which could promote in 
situ immunecomplex deposition and inflammatory processes.8-10 Furthermore, 
the effects of anti-dsDNA antibodies on the expression of different cytokines 
have drawn attention. The observation by Sun et al. that normal human PBMCs 
incubated with antibodies to DNA from patients with active SLE showed 
diminished proliferation and enhanced secretion of IL-1β, IL-6, IL-8, IL-10 and 
TNF-α reflects the importance of autoantibodies in this inflammatory condition 
beyond immune complex formation.11 
However, B-cells are more than a source of pathogenic autoantibodies 
alone. This is supported by several murine models. Chan et al. created a JHD-
MRL/MpJ-Faslpr mouse expressing B-cells but lacking antibody secretion. 
Despite the absence of circulating Ig these mice developed interstitial nephritis 




and vasculitis.1 The same authors could also demonstrate in another JHD-
MRL/+ murine model that B-cells are required for the development of lupus 
nephritis. Crossing MRL/+ mice with JHD-MRL/lpr mice resulted in lupus prone 
mice without B-cells. These animals did not develop glomerulonephritis and 
had, additionally, reduced amounts of activated T-cells.12 These data 
demonstrate a role for B-cells in the development of SLE apart from the 
secretion of autoantibodies. Obviously, B-cells can be autoreactive in the 
absence of autoantibody production, possibly by their antigen-presenting 
capacity. Antigen-presenting capacity of B-cells contributing to prolonged 
inflammatory responses in autoimmunity has also been suggested in studies on 
renal infiltrates of patients with lupus and ANCA-associated nephritis. Analysis 
of intrarenal B-cell clusters clearly showed an antigen presenting phenotype. 
Interestingly, these B-cell clusters expressed the lymphoid chemokines 
BCA-1/CXCL13 suggesting a B-cell attracting mechanism in inflamed tissue 
similar to secondary lymphoid organs.13 These findings suggest that B-cells in 
systemic lupus, besides being a source of pathogenic autoantibody production, 
also have other pathogenic potentials in this autoimmune disease. 
 
Regulatory B-cells in SLE  
The hypothesis that also B-cells could regulate the autoimmune response has 
further contributed to our understanding of B-cell physiology. These regulatory 
B-cells are characterised by the secretion of IL-10 and TGF-β. In an elegant 
mouse model Fillatreau et al. demonstrated that the course of T-cell dependent 
experimental autoimmune encephalomyelitis (EAE) was strongly influenced by 
IL-10. IL-10 deficient mice failed to recover from induced EAE whereas the 
transfer of purified splenic IL-10 producing B-cells reduced EAE severity. 
Remarkably, induction of IL-10 secretion by B-cells required the concurrent 
ligation of CD40.14 In a similar mouse model Matsushita et al. reported more 
recently that depletion of IL-10 producing B-cells by rituximab before EAE 
induction contributes to a more severe disease and adoptive transfer of B10 





restored this effect.2 In a model of chronic intestinal inflammation B-cells appear 
to suppress the progress of inflammation by downregulating inflammatory 
cascades which are associated with IL-1 upregulation and STAT3 activation.15 
Singh et al. demonstrated in a murine model of allergic airway disease that B-
cells from local lymph nodes are able to induce the conversion of CD4+CD25- 
effector T-cells in Foxp3+ regulatory T-cells via TGF-β. In this model the 
suppressive B-cell function is TGF-β dependent and contributes indirectly to 
disease remission via regulatory T-cells.16 In human immune homeostasis IL-10 
producing B-cells have been shown to be involved as well.17 This rises the 
question whether regulatory B-cells might also play a role in SLE. There are 
controversial data regarding the role of IL-10 in lupus like animal models and in 
human SLE. Yin et al. reported an increased Th1 response and autoantibody 
production in IL-10-deficient MRL-Faslpr mice as compared to IL-10+/+ control 
mice. Besides, these mice developed a more severe glomerulonephritis. These 
data suggest that IL-10 may down-modulate autoantibody production and end-
organ disease in lupus via inhibition of Th1 cytokine production.18 On the other 
hand, continuous administration of anti-interleukin-10 antibodies in NZB/W F1 
mice had a protective effect at the level of proteinuria and glomerulonephritis, 
and substantially delayed onset of autoimmunity.19 Similar beneficial effects of 
antagonistic IL-10 treatment were observed in a clinical study including six SLE 
patients.20 The source of IL-10 secretion, whether T-cell or B-cell derived, needs 
further investigation. Nevertheless, IL-10 seems to possess both 
immunosuppressive and immunostimulatory properties which may explain these 
contradictory results. The fact that SLE patients often benefit from B-cell 
depletion could suggest a minor role of regulatory B-cells in established 
disease. Unfortunately, there are no phenotypic markers for so called regulatory 
B-cells available in animal models and humans. Nevertheless, the previously 
mentioned findings suggest a pivotal role of this B-cell subset in the induction of 
autoimmune diseases such as SLE.   
 
 




Interventions in B-cell homeostasis by B-cell depletion 
Data demonstrating the crucial role of B-cells in the pathogenesis of SLE 
support the idea that B-cell depletion might be an attractive goal for treatment of 





Figure 1. Regulation of B-cell activity in SLE: This figure illustrates different stages of B-cell 
regulation including potential therapeutic targets in systemic lupus erythematosus. The B-cell is 
regulated by B - T cell interaction (costimulation), soluble factors such as B lymphocyte stimulator 
(BLyS) and regulatory cells like regulatory T-cells and regulatory B-cells via IL-10 secretion. The 
figure shows promising therapeutic targets in B-cell regulation in SLE beside B-cell depletion with 
monoclonal chimeric antibody anti-CD20 (1). Therapeutic interventions in B-cell regulation can be 
achieved by blocking costimulation at the level of CD28–CD80/CD86 interaction, the CD154/CD40 
pathway and preventing the CD134/CD134L ligation (2,3 and 4). Additionally, inhibition of binding 
BLyS to its receptors by monoclonal antibody could be a therapeutical target in human SLE as well. 
Regulatory B-cells (Bregs) regulate effector B-cells via IL-10 secretion (5). Possible future 
approaches could address Bregs as an important therapeutic goal to restore the balance between 






The most widely used monoclonal chimeric antibody for B-cell depletion is 
Rituximab®, which is directed against the B-cell specific surface marker CD20. 
Initially, Rituximab® was successfully used in Non Hodgkin Lymphoma and over 
the last years data have become available regarding anti-CD20 therapy in the 
course of autoimmune diseases such as rheumatoid arthritis and systemic 
lupus erythematosus.21-23 In open studies the clinical response in SLE patients, 
as assessed by SLAM, to B-cell depletion was very promising. Gunnarsson et 
al. demonstrated a clinical benefit for cyclophosphamide resistant lupus 
nephritis. Both urinary sediment abnormalities and histopathological features 
improved.24 On the other hand SLE patients without renal involvement do not 
seem to improve in disease activity as assessed by SLEDAI or BILAG after 
rituximab infusion as concluded from the Explorer trial, although this may, at 
least in part, be due to the design of that study. 25 
Because treatment with Rituximab® targets immature, naive and 
memory B-cells expressing CD20 but not plasma cells which are lacking this 
marker, additional strategies may be needed for long term efficacy. Another 
limitation of Rituximab® is its chimeric structure. A recent study investigated the 
variabilty in response to B-cell depleting therapy due to human anti-chimeric 
antibodies. These antibodies are evidently frequently present in SLE patients 
and associated with a far lower extent of B-cell depletion as compared to 
patients without these antibodies.26 Humanized monoclonal antibodies to CD20 
(Ocrelizumab®) are currently also evaluated in SLE patients to assess their 
promised improvement in tolerance and efficacy. However, also humanized 
anti-CD20 antibodies fail to deplete long lasting plasma B-cells. Indeed, anti-
dsDNA autoantibodies are decreased but persist after B-cell depletion in almost 
all SLE patients.27  
Apart from depletion of CD20+ B-cells this treatment indirectly affects 
also the T-cell compartment. Previous studies have shown that  there are less 
activated but increased numbers of FoxP3+ regulatory T-cells in the peripheral 
blood of SLE patients following B-cell depleting therapy.28 In another study the 
suppressive capacity of regulatory T-cells improved significantly.29 The effect of 




B-cell depletion on regulatory B-cells in lupus models or patients has not been 
evaluated so far. From the experimental studies in EAE mice one would 
conclude that B-cell depletion in patients in remission of lupus disease could, 
possibly, be contraindicated but there are no clinical hints in human trials 
available supporting this hypothesis.2  
An unresolved problem is the lack of specific surface markers 
identifying these regulatory B-cells which makes it difficult to monitor these cells 
in clinical practice. Identification of a specific regulatory B-cell marker would be 
helpful for therapeutic modulation of this population. So far one has to assume 
that anti-CD20 therapy also depletes the regulatory B-cell subset. Taken 
together B-cell depletion seems to improve the clinical course of some SLE 
patients but controlled studies have not confirmed this suggestion until now. 
Apart from B-cell depletion, B-T cell interaction and B-cell stimulating factors are 
other attractive goals to modulate B-cell activity. 
 
Interventions in B-T cell interaction 
The impact of T-cells on B-cells via costimulation is well known. The relevance 
of co-stimulatory molecules for immune-mediated disease was investigated in 
several murine models resembling human SLE. Blockade of the CD28–
CD80/CD86 interaction and the CD154/CD40 pathway resulted in amelioration 
of disease in these mouse models.30;31 A delay in disease onset as assessed by 
anti-DNA antibody titer, development of fixed proteinuria, histological evidence 
of renal damage, and survival could also be observed in NZB/NZW F1 mice 
after a single infusion of CTLA4Ig.32 CTLA4Ig is homologue to CD28 and binds 
to CD80/CD86 with high affinity. Infusion of CTLA4Ig obviously results in 
downregulation of B-cell activity by blocking the CD28–CD80/CD86 pathway. In 
human trials CTLA4Ig (Abatacept®) has been successfully evaluated in 
rheumatoid arthritis.33 Controlled studies in patients with SLE are currently not 
available. A benefical effect can be expected as high levels of co-stimulatory 
molecules, especially CD80 and CD86 on B-cells, were also found in human 





assessed by the SLEDAI score. Surprisingly, CD80 and CD86, which are 
usually found on APCs, were also found on T-cells of patients with SLE. 
However, the significance of this finding for disease development and activity 
remained unclear in this study.35 Furthermore, expression of CD134L has been 
shown to be up-regulated in proliferative lupus nephritis, suggesting a role for 
the CD134-CD134L pathway in its pathogenesis. Additionally, CD134 
expression was correlated with disease activity and associated with renal 
involvement in human SLE.36 A current study in BXBS mice demonstrated that 
blocking this interaction could be an effective alternative target to attenuate 
lupus nephritis.37 A co-stimulatory antagonist against CD154 (CD40L) has also 
been examined as a possible therapeutic approach in human (renal) SLE but 
this was not fruitful, as short-term administration of the anti-CD154 was 
associated with life-threatening prothrombotic activity despite initial encouraging 
data in serology and renal function of the patients.38 
 
Interventions in B-cell stimulation by targeting soluble factors 
An alternative approach to targeting costimulatory signals is to block cytokines 
that are required for B-cell function. The TNF-like molecule B lymphocyte 
stimulator (BLyS), also known as BAFF (B-cell activating factor from the tumor 
necrosis factor family) is essential for B-cell survival and development and is 
mainly produced by monocytes and macrophages. The biologically active 
soluble form of BlyS binds to its 3 receptors TACI (transmembrane activator and 
calcium modulator ligand interactor), BCMA (B lymphocyte maturation antigen) 
and BAFF-R (BAFF receptor) expressed on B lymphocytes with highest binding 
intensity among mature B-cells.39 The homologous molecule APRIL (a 
proliferation-inducing ligand) mediates similar effects to those of BLyS after 
binding to TACI and BCMA. Elevated serum levels of BLyS have been detected 
in murine SLE models (MRL/Mp-lpr/lpr). In this lupus model serum levels of BLyS 
seem to be associated with kidney damage whereas treatment with soluble 
BLyS receptor significantly prolonged survival of lupus mice.40 Zhang et al. 
demonstrated an association of soluble BLyS levels with increased production 




of anti-dsDNA antibodies studying 150 patients’ sera.41 More recently, a 
correlation between plasma BLyS levels and disease activity as assessed by 
SELENA-SLEDAI in SLE patients has been shown.42 These findings indicate 
that increased BLyS levels may contribute to the development of human SLE 
and suggest BLyS to be a crucial factor in B-cell regulation being a potential 
novel therapeutic target. Currently, belimumab (LymphoStat-B), a human 
monoclonal antibody that binds to soluble BLyS preventing binding to its 
receptors, is evaluated regarding activity and safety in a multicenter phase I trial 
in SLE patients. The authors showed that belimumab is safe and biologically 
active but significant improvement of disease activity in these patients was not 
achieved. Furthermore, a decrease of CD20+ B-cells occurred after treatment 
with belimumab.43 Interestingly, BLyS levels increase after B-cell depletion with 
rituximab and decrease with repopulation of B-cells in SLE and RA patients.44 
Taken together, these data show an important role of BLyS in the regulation of 




The provided data demonstrate that activated B-cells have a multifunctional role 
in the pathogenesis of systemic lupus erythematosus. Besides their diverse 
properties promoting pathogenic events in lupus recent data suggest that an 
altered regulation of so-called regulatory B-cells contributes to hyperactivation 
of B-cells. Regulatory B-cells characterised by IL-10 secretion could, in addition 
to other factors, play a role in ochestrating the B - T-cell homeostasis in SLE as 
has been shown for other autoimmune diseases. However, the regulatory role 
of IL-10 in SLE has to be explored further. Functional studies on IL-10 
producing B-cells in human SLE are, however, lacking. The balance between 
regulatory B- and T-cells should be investigated in order to get further insight in 
B-cell hyperactivity in SLE. Future efforts should first concentrate on the 





monitoring and specific therapeutic modulation of this population remains 
difficult.  
As mentioned before, B-cell depleting treatment appears effective in 
open series and case reports in SLE, but controlled studies are not conclusive 
until now. Although this may be due to study design, a further analysis of 
immunopathological changes following B-cell depleting therapy is necessary, 
including an analysis of changes in regulatory B-cells as well as T-cells. 
Furthermore, the immunopathological effects of intervention in B-T cell 
interaction and B-cell activating factors should be studied. Insights from these 
studies may not only help to understand the efficacy or lack of efficiency of  
different ways of B-cell targeting, but will also increase our understanding of 
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